{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:34:09Z","timestamp":1786995249708,"version":"build-2736575974"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA217059"],"award-info":[{"award-number":["R01CA217059"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.omto.2020.08.009","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T11:27:23Z","timestamp":1598009243000},"page":"587-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"Minkyu","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5102-3996","authenticated-orcid":false,"given":"Yanping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn E.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogindra","family":"Vedvyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dessislava","family":"Stefanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine D.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raza","family":"Zarnegar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Ho","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hoon","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Cheol","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonsoo M.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2020.08.009_bib1","first-page":"26","article-title":"Epidemiology of gastric cancer: global trends, risk factors and prevention","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz. Gastroenterol."},{"key":"10.1016\/j.omto.2020.08.009_bib2","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.08.009_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.omto.2020.08.009_bib4","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.3748\/wjg.v22.i8.2403","article-title":"Advanced gastric cancer: current treatment landscape and future perspectives","volume":"22","author":"Digklia","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omto.2020.08.009_bib5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s10120-018-0794-1","article-title":"Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11","volume":"21","author":"Kim","year":"2018","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.omto.2020.08.009_bib6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2014.03.002","article-title":"Unmet needs and challenges in gastric cancer: the way forward","volume":"40","author":"Lordick","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.omto.2020.08.009_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.omto.2020.08.009_bib8","first-page":"912418","article-title":"The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art","volume":"2014","author":"Montori","year":"2014","journal-title":"Int. J. Surg. Oncol."},{"key":"10.1016\/j.omto.2020.08.009_bib9","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2020.08.009_bib10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2020.08.009_bib11","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.08.009_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ctrv.2018.04.004","article-title":"Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: current status and future perspectives","volume":"66","author":"Taieb","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.omto.2020.08.009_bib13","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.08.009_bib14","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T\u00a0cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2020.08.009_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2020.08.009_bib16","doi-asserted-by":"crossref","first-page":"13545","DOI":"10.18632\/oncotarget.14592","article-title":"Intraperitoneal immunotherapy with T\u00a0cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis","volume":"8","author":"Ang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2020.08.009_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-019-0704-y","article-title":"Mesothelin is a target of chimeric antigen receptor T\u00a0cells for treating gastric cancer","volume":"12","author":"Lv","year":"2019","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omto.2020.08.009_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jnci\/djy134","article-title":"Claudin18.2-specific chimeric antigen receptor engineered T\u00a0cells for the treatment of gastric cancer","volume":"111","author":"Jiang","year":"2019","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.omto.2020.08.009_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T\u00a0cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.omto.2020.08.009_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40425-017-0230-9","article-title":"Current approaches to increase CAR T\u00a0cell potency in solid tumors: targeting the tumor microenvironment","volume":"5","author":"Scarf\u00f2","year":"2017","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2020.08.009_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/15419060390262561","article-title":"ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: a potential mechanism by which surgical trauma increases peritoneal metastases","volume":"10","author":"Ziprin","year":"2003","journal-title":"Cell Commun. Adhes."},{"key":"10.1016\/j.omto.2020.08.009_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.5230\/jgc.2012.12.3.140","article-title":"Expression of intercellular adhesion molecule-1 and E-selectin in gastric cancer and their clinical significance","volume":"12","author":"Jung","year":"2012","journal-title":"J.\u00a0Gastric Cancer"},{"key":"10.1016\/j.omto.2020.08.009_bib23","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1158\/1078-0432.CCR-17-2008","article-title":"CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors","volume":"23","author":"Min","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.08.009_bib24","doi-asserted-by":"crossref","first-page":"14366","DOI":"10.1038\/s41598-017-14749-3","article-title":"Micromolar affinity CAR T\u00a0cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity","volume":"7","author":"Park","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2020.08.009_bib25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Bass","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.omto.2020.08.009_bib26","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-16-2211","article-title":"Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas project","volume":"23","author":"Sohn","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.08.009_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta Pathol. Microbiol. Scand."},{"key":"10.1016\/j.omto.2020.08.009_bib28","doi-asserted-by":"crossref","first-page":"10634","DOI":"10.1038\/s41598-019-46938-7","article-title":"Manufacturing and preclinical validation of CAR T\u00a0cells targeting ICAM-1 for advanced thyroid cancer therapy","volume":"9","author":"Vedvyas","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2020.08.009_bib29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13277-011-0250-x","article-title":"Optimized labeling of NOTA-conjugated octreotide with F-18","volume":"33","author":"Laverman","year":"2012","journal-title":"Tumour Biol."},{"key":"10.1016\/j.omto.2020.08.009_bib30","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.3748\/wjg.v22.i33.7478","article-title":"Regional but fatal: intraperitoneal metastasis in gastric cancer","volume":"22","author":"Wei","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omto.2020.08.009_bib31","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1126\/science.1208347","article-title":"Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice","volume":"334","author":"Michaud","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.omto.2020.08.009_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.08.009_bib33","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2020.08.009_bib34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s004320050160","article-title":"Greater antitumor efficacy of paclitaxel administered before epirubicin in a mouse mammary carcinoma","volume":"124","author":"Cividalli","year":"1998","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.omto.2020.08.009_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1126\/science.8097338","article-title":"Development of TH1 CD4+ T\u00a0cells through IL-12 produced by Listeria-induced macrophages","volume":"260","author":"Hsieh","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.omto.2020.08.009_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.iy.13.040195.001343","article-title":"Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity","volume":"13","author":"Trinchieri","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omto.2020.08.009_bib37","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1126\/science.270.5238.908.a","article-title":"IL-12 deaths: explanation and a puzzle","volume":"270","author":"Cohen","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.omto.2020.08.009_bib38","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.omto.2020.08.009_bib39","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-10-0735","article-title":"Tumor-specific CD8+ T\u00a0cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts","volume":"70","author":"Kerkar","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.08.009_bib40","first-page":"372","article-title":"Mechanisms of resistance to CAR T\u00a0cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2020.08.009_bib41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T\u00a0cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2020.08.009_bib42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors","volume":"9","author":"D\u2019Aloia","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omto.2020.08.009_bib43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ijc.10514","article-title":"ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer","volume":"100","author":"Maruo","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omto.2020.08.009_bib44","first-page":"511","article-title":"Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer","volume":"9","author":"Maeda","year":"2002","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.omto.2020.08.009_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s101200050067","article-title":"Decrease in ICAM-1 expression on gastric cancer cells is correlated with lymph node metastasis","volume":"2","author":"Fujihara","year":"1999","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.omto.2020.08.009_bib46","first-page":"31","article-title":"Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis","volume":"4","author":"Ogawa","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.08.009_bib47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/cancers9110153","article-title":"Role of LFA-1 and ICAM-1 in cancer","volume":"9","author":"Reina","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omto.2020.08.009_bib48","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1245\/s10434-011-2029-0","article-title":"Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma","volume":"19","author":"Buitrago","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.omto.2020.08.009_bib49","doi-asserted-by":"crossref","first-page":"11720","DOI":"10.1038\/s41598-018-29604-2","article-title":"ICAM1 expression is induced by proinflammatory cytokines and associated with TLS formation in aggressive breast cancer subtypes","volume":"8","author":"Figenschau","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2020.08.009_bib50","doi-asserted-by":"crossref","first-page":"14710","DOI":"10.1073\/pnas.1408556111","article-title":"ICAM-1 as a molecular target for triple negative breast cancer","volume":"111","author":"Guo","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2020.08.009_bib51","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T\u00a0cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.08.009_bib52","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific T\u00a0cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omto.2020.08.009_bib53","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T\u00a0cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omto.2020.08.009_bib54","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/imt-2016-0008","article-title":"A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial","volume":"8","author":"Mayor","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.omto.2020.08.009_bib55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T\u00a0cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2020.08.009_bib56","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.immuni.2013.03.003","article-title":"Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells","volume":"38","author":"Ma","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.omto.2020.08.009_bib57","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T\u00a0cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omto.2020.08.009_bib58","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2020.08.009_bib59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1634\/theoncologist.10-2-112","article-title":"Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy","volume":"10","author":"Sugarbaker","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.omto.2020.08.009_bib60","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in\u00a0vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2020.08.009_bib61","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T\u00a0cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omto.2020.08.009_bib62","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omto.2020.08.009_bib63","doi-asserted-by":"crossref","first-page":"e99573","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T\u00a0cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.omto.2020.08.009_bib64","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1126\/science.aav8692","article-title":"Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.omto.2020.08.009_bib65","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omto.2020.08.009_bib66","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","article-title":"Local delivery of interleukin-12 using T\u00a0cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice","volume":"18","author":"Chinnasamy","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.08.009_bib67","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2020.08.009_bib68","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T\u00a0cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2020.08.009_bib69","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T\u00a0cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.omto.2020.08.009_bib70","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 engineering improves CAR T\u00a0cell function in solid tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2020.08.009_bib71","doi-asserted-by":"crossref","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T\u00a0cells eradicate ovarian tumors in\u00a0vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2020.08.009_bib72","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T\u00a0cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.08.009_bib73","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.4049\/jimmunol.1300652","article-title":"Cutting edge: IL-12 and type I IFN differentially program CD8 T\u00a0cells for programmed death 1 re-expression levels and tumor control","volume":"191","author":"Gerner","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2020.08.009_bib74","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1074\/jbc.270.11.5864","article-title":"Structure-function analysis of the p35 subunit of mouse interleukin 12","volume":"270","author":"Zou","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omto.2020.08.009_bib75","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.08.009_bib76","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1096\/fj.201800636R","article-title":"Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression","volume":"33","author":"Brehm","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.omto.2020.08.009_bib77","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T\u00a0cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2020.08.009_bib78","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2020.08.009_bib79","series-title":"AJCC Cancer Staging Manual, Sixth Edition (Springer)","first-page":"xiv","year":"2002"},{"key":"10.1016\/j.omto.2020.08.009_bib80","first-page":"443","article-title":"Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies","volume":"125","author":"Reiner","year":"1986","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omto.2020.08.009_bib81","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2967\/jnumed.109.066902","article-title":"A novel facile method of labeling octreotide with 18F-fluorine","volume":"51","author":"Laverman","year":"2010","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.omto.2020.08.009_bib82","doi-asserted-by":"crossref","first-page":"e90064","DOI":"10.1172\/jci.insight.90064","article-title":"Longitudinal PET imaging demonstrates biphasic CAR T\u00a0cell responses in survivors","volume":"1","author":"Vedvyas","year":"2016","journal-title":"JCI Insight"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770520301261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770520301261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:35:22Z","timestamp":1778880922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770520301261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":82,"alternative-id":["S2372770520301261"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2020.08.009","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2020.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}